Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Durantel

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Antiviral Research|January 5, 2023
Therapies against chronic hepatitis B infections: The times they are a-changin', but the changing is slow!David Durantel
Best Practice & Research. Clinical Gastroenterology|August 5, 2017
New treatments to reach functional cure: Virological approachesDavid Durantel
Antiviral Therapy|June 3, 2010
Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?David Durantel
Current Opinion in Investigational Drugs (London, England : 2000)|August 4, 2009
Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infectionDavid Durantel
Journal of Hepatology|April 17, 2016
New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virusDavid Durantel, Fabien Zoulim
Cold Spring Harbor Perspectives in Medicine|April 3, 2015
Antiviral therapies and prospects for a cure of chronic hepatitis BFabien Zoulim, David Durantel
Cell Stem Cell|March 3, 2018
Who Defends the Stem Cell's Citadel?Hélène Strick-Marchand, David Durantel
Current Opinion in Investigational Drugs (London, England : 2000)|March 3, 2007
Glucosidase inhibitors as antiviral agents for hepatitis B and CDavid Durantel, Christine Alotte, Fabien Zoulim
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2017
Novel targets for hepatitis B virus therapyBarbara Testoni, David Durantel, Fabien Zoulim
Plos Pathogens|May 12, 2025
TRIM proteins: A 'swiss army knife' of antiviral immunityElise Chabot, David Durantel, Julie Lucifora
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Antiviral Research|January 5, 2023
Therapies against chronic hepatitis B infections: The times they are a-changin', but the changing is slow!David Durantel
Best Practice & Research. Clinical Gastroenterology|August 5, 2017
New treatments to reach functional cure: Virological approachesDavid Durantel
Antiviral Therapy|June 3, 2010
Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?David Durantel
Current Opinion in Investigational Drugs (London, England : 2000)|August 4, 2009
Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infectionDavid Durantel
Journal of Hepatology|April 17, 2016
New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virusDavid Durantel, Fabien Zoulim
Cold Spring Harbor Perspectives in Medicine|April 3, 2015
Antiviral therapies and prospects for a cure of chronic hepatitis BFabien Zoulim, David Durantel
Cell Stem Cell|March 3, 2018
Who Defends the Stem Cell's Citadel?Hélène Strick-Marchand, David Durantel
Current Opinion in Investigational Drugs (London, England : 2000)|March 3, 2007
Glucosidase inhibitors as antiviral agents for hepatitis B and CDavid Durantel, Christine Alotte, Fabien Zoulim
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2017
Novel targets for hepatitis B virus therapyBarbara Testoni, David Durantel, Fabien Zoulim
Plos Pathogens|May 12, 2025
TRIM proteins: A 'swiss army knife' of antiviral immunityElise Chabot, David Durantel, Julie Lucifora
Pageof 13